Munich - Delayed Quote EUR

Scholar Rock Holding Corp (2QK.MU)

30.20

+2.00

+(7.09%)

At close: April 25 at 8:17:20 AM GMT+2

Why Scholar Rock Holding Stock Topped the Market Today

Biotech stock Scholar Rock (NASDAQ: SRRK) was popular among investors on Wednesday after a positive new analyst note on the company made the rounds. Scholar Rock targets relatively uncommon disorders that might lack effective treatments. Its current lead drug candidate -- apitegromab, a medicine that preserves muscle mass in patients with two types of spinal muscular atrophy (SMA) -- is under review for approval by both the U.S. Food and Drug Administration and the European Union's European Medicines Agency (EMA).

Motley Fool 2 days ago

SRRK
Scholar Rock Holding Corp (SRRK) Q4 2024 Earnings Call Highlights: Clinical Success and ...

Scholar Rock Holding Corp (SRRK) reports promising clinical results and strategic preparations for the launch of apitegromab, while navigating regulatory and competitive landscapes.

GuruFocus.com 4 days ago

SRRK
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., April 18, 2025--Scholar Rock (NASDAQ: SRRK; the "Company"), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, today announced that the company granted inducement equity awards covering an aggregate of 156,650 shares of its common stock to 19 newly hired employees, consisting of inducement stock options to purchase an aggregate of 89,515 shares of common stock and i

Business Wire 7 days ago

SRRK
Exploring 3 High Growth Tech Stocks In The US Market

In the last week, the United States market has been flat, but over the past 12 months, it has risen by 8.4%, with earnings expected to grow by 14% per annum in the coming years. In this environment, identifying high-growth tech stocks can be crucial for investors seeking to capitalize on potential opportunities within a dynamic sector poised for expansion.

Simply Wall St. 22 days ago

AVPT

AVPTW

SRRK
FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy

CAMBRIDGE, Mass., March 25, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for apitegromab, an investigational muscle-targeted treatment that is being developed to provide clinically meaningful improvement in motor function for p

Business Wire last month

SRRK
Scholar Rock SMA drug shows muscle function benefit

Scholar Rock’s stock is due to drop by 7.49% following the news, according to pre-market estimates.

Clinical Trials Arena last month

SRRK

GLDAF
Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

CAMBRIDGE, Mass., March 16, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that new efficacy and safety data from the Phase 3 pivotal SAPPHIRE trial (NCT05156320) will be presented in multiple clinical presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Sc

Business Wire last month

SRRK
When Can We Expect A Profit From Scholar Rock Holding Corporation (NASDAQ:SRRK)?

Scholar Rock Holding Corporation ( NASDAQ:SRRK ) is possibly approaching a major achievement in its business, so we...

Simply Wall St. last month

SRRK
Q4 2024 Scholar Rock Holding Corp Earnings Call

Q4 2024 Scholar Rock Holding Corp Earnings Call

Thomson Reuters StreetEvents last month

SRRK
Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress

CAMBRIDGE, Mass., February 27, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today reported financial results and corporate updates for the full year ended December 31, 2024.

Business Wire last month

SRRK
Scholar Rock to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., February 25, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will participate in the following upcoming investor conferences:

Business Wire last month

SRRK
Is Scholar Rock Holding (SRRK) One of the Oversold Biotech Stocks to Buy Now?

We recently published a list of 10 Oversold Biotech Stocks to Buy Now. In this article, we are going to take a look at where Scholar Rock Holding Corporation (NASDAQ:SRRK) stands against other oversold biotech stocks to buy now. Biotech Sector Performance and Challenges in 2024: Biotechnology stocks are among the most volatile in the […]

Insider Monkey last month

SRRK
Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

CAMBRIDGE, Mass., February 21, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, announced today that it will present additional data from its Phase 3 SAPPHIRE clinical trial (NCT05156320) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference being held March 16

Business Wire 2 months ago

SRRK
Scholar Rock to Host Conference Call to Discuss Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Update on February 27, 2025

CAMBRIDGE, Mass., February 10, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will host a conference call to discuss its fourth quarter and full year 2024 financial results and provide a business update on Thursday, February 27, 2025, at 8:15am ET.

Business Wire 2 months ago

SRRK
Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA)

CAMBRIDGE, Mass., January 29, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced the submission of a Biologics License Application to the U.S. Food and Drug Administration (FDA) for apitegromab, a muscle-targeted therapy designed and developed to provide clinically meaningfu

Business Wire 2 months ago

SRRK
Scholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition

CAMBRIDGE, Mass., January 29, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, announced today that Lisa Wyman has been appointed to the new role of Chief Technical and Quality Officer (CTQO) to support the Company’s ongoing growth and evolution to becoming a fully integrated biopharma co

Business Wire 2 months ago

SRRK
Here’s Why Scholar Rock Holding Corporation (SRRK) Is Skyrocketing

We recently compiled a list of the Why These 24 Stocks Are Skyrocketing. In this article, we are going to take a look at where Scholar Rock Holding Corporation (NASDAQ:SRRK) stands against the other stocks. One of the strongest stock market anomalies is the momentum effect, which is the tendency of recent past winners to outperform […]

Insider Monkey 3 months ago

SRRK
Scholar Rock Highlights 2025 Strategic Priorities

CAMBRIDGE, Mass., January 08, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today provided recent corporate updates and highlighted upcoming priorities for 2025.

Business Wire 3 months ago

SRRK
Scholar Rock to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., January 02, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 9:45 a.m. PT (12:45 p.m. ET).

Business Wire 3 months ago

SRRK
Why Is Scholar Rock Holding Corporation (SRRK) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?

We recently compiled a list of the 10 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds. In this article, we are going to take a look at where Scholar Rock Holding Corporation (NASDAQ:SRRK) stands against the other small-cap biotech stocks. Revolutionizing Healthcare and Economy: The Rapid Growth of Biotechnology The biotechnology sector is […]

Insider Monkey 4 months ago

SRRK

Performance Overview

Return	2QK.MU	S&P 500 (^GSPC)
YTD	-29.77%	-6.06%
1-Year	+127.07%	+9.44%
3-Year	+243.18%	+28.61%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Scholar Rock Holding Corp (2QK.MU)

Why Scholar Rock Holding Stock Topped the Market Today

Scholar Rock Holding Corp (SRRK) Q4 2024 Earnings Call Highlights: Clinical Success and ...

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Exploring 3 High Growth Tech Stocks In The US Market

FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy

Scholar Rock SMA drug shows muscle function benefit

Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

When Can We Expect A Profit From Scholar Rock Holding Corporation (NASDAQ:SRRK)?

Q4 2024 Scholar Rock Holding Corp Earnings Call

Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress

Scholar Rock to Participate in Upcoming Investor Conferences

Is Scholar Rock Holding (SRRK) One of the Oversold Biotech Stocks to Buy Now?

Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Scholar Rock to Host Conference Call to Discuss Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Update on February 27, 2025

Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA)

Scholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition

Here’s Why Scholar Rock Holding Corporation (SRRK) Is Skyrocketing

Scholar Rock Highlights 2025 Strategic Priorities

Scholar Rock to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Why Is Scholar Rock Holding Corporation (SRRK) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?

Performance Overview